Previous Close | 7.96 |
1-Year Change | 4.05% |
6-Months Change | 45.52% |
3-Months Change | 29.43% |
Moving Avg (50d) | 7.7082 |
Moving Avg (200d) | 6.1729 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 1.51B |
Beta (3-Years) | 1.2 |
Revenue Growth (ttm) | 33.18% |
Net Profit Margin (ttm) | -74.43% |
Return On Assets (ttm) | -45.2% |
EPS (ttm) | -1.25 |
PE Ratio (ttm) | -6.37 |
Dividend Yield | % |
Asset Description: | BioCryst Pharmaceuticals, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Buy |
Forecast Date: | 2024-09-13 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
7.801 | 7.562 | 7.403 | 7.164 | 6.766 | 6.368 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.